Falko Markus Heinemann

Dr. Falko Markus Heinemann

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in Colombia Medica
Verified
Journal Article
Open access
CZChris Zielinski
Chris Zielinski
MWMargaret A. Winker
Margaret A. Winker
RARakesh Aggarwal
Rakesh Aggarwal
LFLorraine E. Ferris
Lorraine E. Ferris
FHFalko Markus Heinemann
Falko Markus Heinemann
FHFarrokh Habibzadeh
Farrokh Habibzadeh
This statement revises our earlier “WAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications” (January 20, 2023). The revision reflects the proliferation of chatbots and their expanding use in scholarly publishing over the last few months, as well as emerging concerns regarding lack of authenticity of content when using chatbots. These recommendations are intended to inform editors and help them develop policies for the use of chatbots in papers published in their journals. They aim to help authors and reviewers understand how best to attribute the use of chatbots in their work and to address the need for all journal editors to have access to manuscript screening tools. In this rapidly evolving field, we will continue to modify these recommendations as the software and its applications develop.


1 January 2009 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Closed access
PDF file
FHFalko Markus Heinemann
Falko Markus Heinemann
The Luminex-based human leukocyte antigen (HLA) antibody screening technology is widespread used in laboratories affiliated to kidney transplantation programs and enables both screening (i.e. the definition of positive or negative antibody status) and antibody identification with high sensitivity and specificity. HLA typing at different levels of resolution with Luminex technology uses sequence-specific oligonucleotide probes bound to color-coded microbeads in order to identify HLA alleles encoded by the DNA sample. In general, the Luminex technology for histocompatibility analyses provides rapid sample processing in a 96-well format combined with limited technical complexity which means high cost efficiency.

4 February 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AKArtur Kibler
Artur Kibler
BBBettina Budeus
Bettina Budeus
EHEkaterina Homp
Ekaterina Homp
KBKevin Bronischewski
Kevin Bronischewski
VBVictoria Berg
Victoria Berg
MSMarc Seifert
Marc Seifert
Human memory B cells (MBCs) are generated and diversified in secondary lymphoid tissues throughout the organism. A paired immunoglobulin (Ig)-gene repertoire analysis of peripheral blood (PB) and splenic MBCs from infant, adult, and elderly humans revealed that throughout life, circulating MBCs are comprehensively archived in the spleen. Archive MBC clones are systematically preserved and uncoupled from class-switching. Clonality in the spleen increases steadily, but boosts at midlife, thereby outcompeting small clones. The splenic marginal zone (sMZ) represents a primed MBC compartment, generated from a stochastic exchange within the archive memory pool. This is supported by functional assays, showing that PB and splenic CD21+ MBCs acquire transient CD21high expression upon NOTCH2-stimulation. Our study provides insight that the human MBC system in PB and spleen is composed of three interwoven compartments: the dynamic relationship of circulating, archive, and its subset of primed (sMZ) memory changes with age, thereby contributing to immune aging.

Verified
Journal Article
Open access
PDF file
HGHana Guberina
Hana Guberina
RMRafael Tomoya Michita
Rafael Tomoya Michita
Sebastian DolffSebastian Dolff
Sebastian Dolff
ABAnja Bienholz
Anja Bienholz
Mirko TrillingMirko Trilling
Mirko Trilling
VRVera Rebmann
Vera Rebmann
The expression modulation of the immunosuppressive non-classical Human leukocyte antigen-G (HLA-G) molecule and its soluble isoforms is an immune evasion strategy being deployed by cytomegalovirus (CMV). The +3142 C>G single nucleotide polymorphism (SNP) located within the 3′ untranslated region (3′UTR) is of crucial importance for the regulation of HLA-G expression. Therefore, we analyzed the influence of the +3142 C>G HLA-G SNP on the occurrence of CMV infection in a cohort of 178 living-donor kidney recipients and their 178 corresponding donors. In addition, soluble HLA-G (sHLA-G) levels were quantified before and after transplantation. The presence of the HLA-G +3142 CC genotype in recipients, but not donors of our cohort as along with elevated sHLA-G levels (≥ 6.1 ng/mL) were associated with higher susceptibility to CMV infection after transplantation. Our results provided evidence that i) HLA-G is implicated in the establishment of CMV after living-donor kidney transplantation and ii) recipient HLA-G +3142 CC genotype and sHLA-G concentration levels could represent important predictive risk markers for CMV infection.

7 August 2019 in Cells
Verified
Journal Article
Open access
PDF file
HRHana Rohn
Hana Rohn
RMRafael Tomoya Michita
Rafael Tomoya Michita
SSSabine Schramm
Sabine Schramm
Sebastian DolffSebastian Dolff
Sebastian Dolff
AGAnja Gäckler
Anja Gäckler
VRVera Rebmann
Vera Rebmann
Human leukocyte antigen (HLA)-E is important for the regulation of anti-viral immunity. BK polyomavirus (BKPyV) reactivation after kidney transplant is a serious complication that can result in BKPyV-associated nephropathy (PyVAN) and subsequent allograft loss. To elucidate whether HLA-E polymorphisms influence BKPyV replication and nephropathy, we determined the HLA-E genotype of 278 living donor and recipient pairs. A total of 44 recipients suffered from BKPyV replication, and 11 of these developed PyVAN. Homozygosity of the recipients for the HLA-E*01:01 genotype was associated with the protection against PyVAN after transplant (p = 0.025, OR 0.09, CI [95%] 0.83–4.89). Considering the time course of the occurrence of nephropathy, recipients with PyVAN were more likely to carry the HLA-E*01:03 allelic variant than those without PyVAN (Kaplan–Meier analysis p = 0.03; OR = 4.25; CI (95%) 1.11–16.23). Our findings suggest that a predisposition based on a defined HLA-E genotype is associated with an increased susceptibility to develop PyVAN. Thus, assessing HLA-E polymorphisms may enable physicians to identify patients being at an increased risk of this viral complication.